Sara Tolaney
MD, MPH
Chief, Division of Breast Oncology
👥Biography 个人简介
Dr. Sara Tolaney is a leading breast oncologist at Dana-Farber who has contributed substantially to TROP2-directed ADC therapy. She has participated in TROPiCS-02 and other sacituzumab govitecan trials and has investigated TROP2 expression as a predictive biomarker. Her broad breast oncology research program includes systemic therapy optimization in TNBC and HR-positive metastatic breast cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Sara Tolaney 的研究动态
Follow Sara Tolaney's research updates
留下邮箱，当我们发布与 Sara Tolaney（Dana-Farber Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment